Covaxin, manufactured by Bharat Biotech, is still awaiting a go ahead from the Technical Advisory Group (TAG) of the World Health Organization (WHO) for Emergency Use Listing (EUL). TAG has sought additional clarifications from Bharat Biotech and is slated to meet on November 3 to give its final decision on EUL risk-benefit assessment for global use of covaxin.
The WHO clearance is much awaited as it will be a significant step in the acceptance of the vaccine by foreign countries and make overseas travel easy for people who have taken this vaccine.
As shared before, data submitted by Bharat Biotech had revealed that Phase III clinical trials of Covaxin had demonstrated an efficacy rate of 77.8 per cent. The expression of interest for EUL was submitted in April by Bharat Biotech. Covid-19 vaccines manufactured by Pfizer-BioNTech, US pharma majors Johnson & Johnson, Moderna, China’s Sinopharm and Oxford-AstraZeneca have been granted emergency use listing by WHO till now.